RxDoctor Payments Data

Lewis Porter, MD

Surgery · Benton, ARNPI 1407883044

Payments from drug & device makers

$3,042in general payments, 2019–2025

Across 86 payments — averaging $35.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • Kerecis Limited$241
  • Smith+Nephew$210
  • TELA Bio, Inc.$200
  • Musculoskeletal Transplant Foundation Inc.$200
  • Phathom Pharmaceuticals, Inc.$171
  • plus $951 from 23 others

What the payments were for

  • Travel & lodging$80927%
  • Food & beverage$2,23373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,042 in reported general payments places this provider in the 55th percentile of 227 surgery providers in Arkansas.

See all surgery providers in Arkansas

Medicare billing

Part B allowed, 2024
$180,236
Medicare patients
532
Services billed
1,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide83$62,143
VoqueznaVonoprazan Fumarate19$12,007
Dexlansoprazole DrDexlansoprazole49$11,830
Pantoprazole Sodium1,054$7,236
Sucralfate273$6,308
SantylCollagenase Clostridium Hist.13$4,571
CholestyramineCholestyramine (With Sugar)71$3,892
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,586
Colesevelam Hcl20$2,046
Ursodiol32$1,827
Dicyclomine Hcl115$1,603
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen106$597
Omeprazole56$451
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$444
Clindamycin Hcl26$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Phathom Pharmaceuticals, Inc.Voquezna$171$12,00719 claims
Smith+NephewSantyl$210$4,57113 claims
Braintree Laboratories, Inc.Sutab$11$3,58622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 227 surgery providers in Arkansas.

Other surgery in Benton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →